Biochemistry-first molecular monograph · Version 5.0 · Updated 23 August 2026
Ipamorelin
Selective GHSR1a agonism and GH secretion
A short-lived pentapeptide activates GHSR1a and produces a temporally resolved GH pulse in humans.
This monograph evaluates ipamorelin as an independent pentapeptide agonist of the growth-hormone secretagogue receptor. It excludes CJC-1295 combinations and does not transfer data from ghrelin, other GHRPs or oral ghrelin agonists.
This monograph begins with the molecule and follows the causal chain through biochemistry, cellular mechanism, exposure and integrated physiology. Population studies enter only at the terminal stress-test: useful for the proposition actually tested, incapable of defining the molecule or replacing the causal model.
Epistemological position
The causal chain carries the science.
Identity establishes what exists. Biochemistry establishes what can react. Pharmacology establishes whether the reaction is reachable. Physiology establishes what the system does with it. Statistical human observation comes last and adjudicates only the route, exposure, population and outcome actually studied.
A population average cannot identify a molecule, create a mechanism or decide an individual response. A demonstrated mechanism remains bounded by the causal step shown; a terminal study can confirm or refute its translation under specified conditions, never rewrite the underlying chemistry.
Molecular dossier
The entity before the outcome.
- ENTITY
- Defined pentapeptide; independent of all GHRH analogues
- BIOCHEMICAL CLASS
- Ghrelin-receptor secretagogue
- PRIMARY SYSTEM
- GHSR1a → pituitary GH and gastrointestinal neural signalling
- IDENTITY BOUNDARY
- Ipamorelin evidence cannot be transferred from ghrelin, other GHRPs, oral ghrelin agonists or CJC combinations. Route and pulse kinetics are part of identity-in-use.
Action ledger
Describe the action before judging its value.
Benefit is a downstream clinical judgement. The scientific object is the action itself: what moves, under which exposure, in which biological state, and where the inference stops.
Attributed biochemical action
A short-lived pentapeptide activates GHSR1a and produces a temporally resolved GH pulse in humans.
Exposure and reachability
In healthy male volunteers receiving intravenous infusions, pharmacokinetics were dose proportional, terminal half-life was approximately two hours, and GH release peaked at about 0.67 hours. These data belong to the intravenous protocol studied.
Physiological direction is contextual
Ipamorelin sits inside the ghrelin–growth-hormone network, where nutritional state, sleep, glucose regulation, pituitary reserve and feedback through IGF-1 modify the response. A transient GH pulse is a proximal physiological event. Whether it improves motility, recovery or composition depends on the downstream system and cannot be inferred from peak amplitude alone.
Individual adjudication boundary
Whether repeated route-specific pulses create a favourable tissue outcome without maladaptive GH/IGF-1 or glucose effects. Receptor selectivity or an acute GH pulse cannot establish sleep, recovery, body-composition or healthy-ageing benefit.
Causal map with terminal adjudication
The scientific hierarchy is explicit.
I–III established for IV exposure and acute GH pharmacodynamics
A short-lived pentapeptide activates GHSR1a and produces a temporally resolved GH pulse in humans.
Class B counterevidence for postoperative ileus; D/E for most optimisation claims
This descriptor applies only to the named route, population and outcome. It neither ranks nor creates the molecule’s biochemical science.
Translation boundary
Whether repeated route-specific pulses create a favourable tissue outcome without maladaptive GH/IGF-1 or glucose effects.
What must not be inferred
Receptor selectivity or an acute GH pulse cannot establish sleep, recovery, body-composition or healthy-ageing benefit.
Historical and international corpus
Old research is not absent research.
Ipamorelin emerged in the late 1990s from the growth-hormone-secretagogue programme. It is not historically ancient, but its human PK and acute endocrine pharmacology are directly measured.
Selectivity and GH release are better established than subcutaneous repeated-use exposure or durable clinical benefit.
Early receptor-selective secretagogue programme
Comparative pharmacology and first human PK established a selective GH-secretagogue identity and an acute response. These early records remain scientifically relevant because they define the molecule rather than merely reporting later outcomes.[1][4]
A gastrointestinal proposition was directly stress-tested
The ileus programme translated pro-motility reasoning into a controlled endpoint. Its neutral primary result narrows that clinical proposition without deleting receptor engagement or acute GH pharmacology.[2][3]
Mechanistic and biochemical calculus
Constraint, measurement and inference are not the same claim.
A biochemical proposition can be powerful without a clinical trial, but its premises, exposure and domain must remain explicit. Each statement below is labelled by the operation that supports it.
Short plasma residence, earlier endocrine peak
In the intravenous human experiment, terminal half-life was about two hours and GH peaked at roughly 0.67 hours. Parent-peptide exposure and downstream hormone response therefore require separate time functions.[1]
Route transformation requires new PK
An intravenous infusion defines complete vascular input. It cannot be transformed into subcutaneous bioavailability or a bedtime exposure curve without absorption and repeated-dose measurements.[1]
Target engagement survived a negative outcome
The controlled ileus endpoint was not significantly improved under the studied regimen. This is a clean example of valid pharmacology failing to guarantee a chosen clinical result.[2]
Complete scientific web editionOpen the full causal analysis and referencesThe decision-grade summary remains above. The complete publication stays available here and as a downloadable PDF.
Causal architecture
From molecular event to organismal hypothesis.
Pulse timing matters
Human IV work places peak GH response well before terminal peptide elimination is complete. Parent-peptide concentration, GH pulse and downstream IGF-1 occupy different time scales; they must be measured separately rather than collapsed into one effect.[1]
Selectivity narrows mechanism, not outcome
Relative selectivity over earlier secretagogues can reduce some off-target endocrine signalling, but it does not guarantee clinical cleanliness. Baseline pituitary reserve, food state, repeated exposure and feedback remain capable of changing the response.[1]
The negative trial localises the failure
A coherent promotility mechanism and animal physiology did not translate into a statistically resolved postoperative primary endpoint. That result constrains the studied clinical proposition while leaving receptor engagement and acute GH pharmacology intact.[2][3]
What is established
✓ Defined pentapeptide
✓ GHSR1a target
✓ Human IV PK and GH response
What remains unresolved
? Other-route pharmacokinetics
? Outcome-specific efficacy
? Longitudinal GH/IGF-1 consequences
Causal hierarchy
Seven evidentiary layers. No category substitution.
Levels I-V build the causal and translational model. Human observations and controlled clinical trials then test the complete proposition under the route, exposure, population and outcome actually studied. A trial is terminal adjudication, not the source of molecular truth.
IMolecular identity and chemistryWhat exact sequence, terminal chemistry, formulation and route exist?
IIBiochemistry and target architectureWhat reactions, binding events and signalling steps are physically possible?
IIICells and ex-vivo tissuesWhat changes in the relevant cell or isolated tissue system?
IVAnimal and in-vivo pharmacologyDoes exposure reach the mechanism in an integrated organism?
VIntegrated physiology and translationHow do tissue state, feedback, dose and individual terrain alter the response?
VIHuman PK and observational signalIs the entity present, tolerated and associated with a signal in humans?
VIIControlled clinical trialsDoes the specified protocol change a prespecified patient-relevant outcome?
Method applied to Ipamorelin
Where this molecule’s evidence can, and cannot, travel.
The complete corpus-wide attribution rules are published in the scientific methodology. This is their molecule-specific application.
Entity rule applied
Ipamorelin evidence cannot be transferred from ghrelin, other GHRPs, oral ghrelin agonists or CJC combinations. Route and pulse kinetics are part of identity-in-use.
Reachability rule applied
In healthy male volunteers receiving intravenous infusions, pharmacokinetics were dose proportional, terminal half-life was approximately two hours, and GH release peaked at about 0.67 hours. These data belong to the intravenous protocol studied. The decisive exposure boundary for Ipamorelin therefore remains molecule-, formulation- and route-specific.
Causal-strength rule applied
A short-lived pentapeptide activates GHSR1a and produces a temporally resolved GH pulse in humans. This places the present causal depth at i–iii established for iv exposure and acute gh pharmacodynamics. That grade describes which links in the mechanism have been demonstrated; it is not a consumer rating and cannot be converted into a general promise of benefit.
Human-adjudication rule applied
Class B counterevidence for postoperative ileus; D/E for most optimisation claims. This terminal descriptor answers only the population, route, exposure and outcome actually observed; it neither upgrades nor cancels a different link in Ipamorelin’s causal chain.
Translation rule applied
Whether repeated route-specific pulses create a favourable tissue outcome without maladaptive GH/IGF-1 or glucose effects. Receptor selectivity or an acute GH pulse cannot establish sleep, recovery, body-composition or healthy-ageing benefit.
Falsification rule applied
The interpretation must change if any of its decisive propositions fail. For Ipamorelin, the predeclared tests are: Absent GH movement after verified exposure would challenge target engagement. Repeated pulses without outcome improvement would refute GH-response-as-clinical-response reasoning. The controlled ileus result already falsifies a reliable benefit claim for the studied regimen and endpoint. These are active boundaries on the conclusion, not research questions appended after a favourable narrative.
Foundational synthesis
Molecular identity and entity resolution
Ipamorelin is a defined pentapeptide growth-hormone secretagogue. Its molecular identity and evidence are independent of every other GH-axis peptide.
Foundational synthesis
Biochemical mechanism and target architecture
Ipamorelin activates the ghrelin receptor GHSR1a and produces growth-hormone release. Receptor selectivity defines mechanism but does not guarantee a meaningful clinical outcome.
Foundational synthesis
In-vivo pharmacology and exposure
In healthy male volunteers receiving intravenous infusions, pharmacokinetics were dose proportional, terminal half-life was approximately two hours, and GH release peaked at about 0.67 hours. These data belong to the intravenous protocol studied.
Foundational synthesis
Integrated physiology and individual terrain
Ipamorelin sits inside the ghrelin–growth-hormone network, where nutritional state, sleep, glucose regulation, pituitary reserve and feedback through IGF-1 modify the response. A transient GH pulse is a proximal physiological event. Whether it improves motility, recovery or composition depends on the downstream system and cannot be inferred from peak amplitude alone.
Foundational synthesis
Terminal human stress-test
A phase 2 postoperative-ileus trial enrolled 117 patients. The primary endpoint was 25.3 hours with ipamorelin versus 32.6 hours with placebo and was not statistically significant (p=0.15).
Foundational synthesis
Counterevidence and causal boundaries
The negative controlled trial is direct evidence that verified receptor pharmacology does not guarantee clinical translation for a chosen indication. It constrains that claim without negating GHSR1a engagement.
Foundational synthesis
Scientific conclusion
Ipamorelin has defined identity, human PK and human target engagement, alongside a clinically important negative trial. Any new proposition must specify route, phenotype and outcome rather than inherit a generic GH narrative.
Extended analysis
Molecular target and endocrine signal
Ipamorelin is a defined pentapeptide that activates GHSR1a, the ghrelin receptor. Receptor activation can stimulate pituitary GH release and can also engage gastrointestinal motility pathways. These are related receptor effects but not interchangeable clinical indications.[1][2][4]
Selectivity relative to earlier GH secretagogues was established in comparative experimental systems and is a pharmacological property, not a guarantee of a clean clinical phenotype. Endocrine response still depends on dose, route, baseline pituitary reserve, feedback through IGF-1, food state and repeated exposure.[1][4]
Extended analysis
Human pharmacokinetics and pharmacodynamics
In healthy male volunteers receiving intravenous infusion, exposure was dose proportional and terminal half-life was approximately two hours. GH release peaked at roughly 0.67 hours. These observations define an intravenous experiment; they do not automatically describe subcutaneous exposure or repeated bedtime administration.[1]
A short plasma half-life can still produce a biological effect that outlasts measurable parent peptide, but duration must be demonstrated rather than assumed. GH pulse, downstream IGF-1 and patient outcome occupy different time scales and require separate measurement.[1]
Extended analysis
Gastrointestinal mechanism
In a rodent postoperative-ileus model, ipamorelin accelerated gastric emptying and reversed impaired contractile responses through a ghrelin-receptor-mediated pathway involving cholinergic excitatory neurons. This provides a coherent mechanism for the indication subsequently tested in humans.[3]
The preclinical result is valuable because it connects receptor, tissue physiology and an outcome. It also demonstrates the limit of mechanistic prediction: a plausible and experimentally supported promotility pathway did not guarantee success of the human primary endpoint.[2][3]
Extended analysis
Controlled human counterevidence
The multicentre phase 2 postoperative-ileus trial randomised 117 bowel-resection patients to intravenous ipamorelin or placebo. Time to the primary composite endpoint was 25.3 hours with ipamorelin and 32.6 hours with placebo, but the difference was not statistically significant (p=0.15).[2]
This negative trial does not invalidate GHSR1a binding, GH release or promotility activity in animals. It constrains the claim that the studied intravenous regimen produces a reliable postoperative clinical benefit. Mechanism and clinical validation answer different questions and can legitimately diverge.[1][2][3]
Extended analysis
Translation beyond the studied indication
Claims concerning sleep, recovery, body composition or healthy ageing are not established by the ileus programme or by an acute GH pulse. Those propositions require their own route-specific pharmacokinetics, functional outcomes and longitudinal metabolic assessment.[1][2]
Repeated stimulation of the GH/IGF-1 axis raises monitoring questions around glucose regulation, oedema, paraesthesia and proliferative context. These are mechanistically foreseeable domains, while their magnitude under a particular regimen remains an empirical question.[1]
Evidence atlas
Every claim keeps its experimental address.
10 claim units are mapped to their evidentiary layer, experimental frame and source records. The layer describes what the evidence can answer; it is not a popularity score.
| Layer | Experimental frame | Finding and boundary | Sources |
|---|---|---|---|
| II/VMechanism and physiological translation | Molecular target and endocrine signal · claim 1 | Ipamorelin is a defined pentapeptide that activates GHSR1a, the ghrelin receptor. Receptor activation can stimulate pituitary GH release and can also engage gastrointestinal motility pathways. These are related receptor effects but not interchangeable clinical indications. | [1][2][4] |
| VIHuman exposure or signal | Molecular target and endocrine signal · claim 2 | Selectivity relative to earlier GH secretagogues was established in comparative experimental systems and is a pharmacological property, not a guarantee of a clean clinical phenotype. Endocrine response still depends on dose, route, baseline pituitary reserve, feedback through IGF-1, food state and repeated exposure. | [1][4] |
| VIHuman exposure or signal | Human pharmacokinetics and pharmacodynamics · claim 1 | In healthy male volunteers receiving intravenous infusion, exposure was dose proportional and terminal half-life was approximately two hours. GH release peaked at roughly 0.67 hours. These observations define an intravenous experiment; they do not automatically describe subcutaneous exposure or repeated bedtime administration. | [1] |
| VIHuman exposure or signal | Human pharmacokinetics and pharmacodynamics · claim 2 | A short plasma half-life can still produce a biological effect that outlasts measurable parent peptide, but duration must be demonstrated rather than assumed. GH pulse, downstream IGF-1 and patient outcome occupy different time scales and require separate measurement. | [1] |
| VIHuman exposure or signal | Gastrointestinal mechanism · claim 1 | In a rodent postoperative-ileus model, ipamorelin accelerated gastric emptying and reversed impaired contractile responses through a ghrelin-receptor-mediated pathway involving cholinergic excitatory neurons. This provides a coherent mechanism for the indication subsequently tested in humans. | [3] |
| VIHuman exposure or signal | Gastrointestinal mechanism · claim 2 | The preclinical result is valuable because it connects receptor, tissue physiology and an outcome. It also demonstrates the limit of mechanistic prediction: a plausible and experimentally supported promotility pathway did not guarantee success of the human primary endpoint. | [2][3] |
| VIIControlled human proposition | Controlled human counterevidence · claim 1 | The multicentre phase 2 postoperative-ileus trial randomised 117 bowel-resection patients to intravenous ipamorelin or placebo. Time to the primary composite endpoint was 25.3 hours with ipamorelin and 32.6 hours with placebo, but the difference was not statistically significant (p=0.15). | [2] |
| VIIControlled human proposition | Controlled human counterevidence · claim 2 | This negative trial does not invalidate GHSR1a binding, GH release or promotility activity in animals. It constrains the claim that the studied intravenous regimen produces a reliable postoperative clinical benefit. Mechanism and clinical validation answer different questions and can legitimately diverge. | [1][2][3] |
| VIHuman exposure or signal | Translation beyond the studied indication · claim 1 | Claims concerning sleep, recovery, body composition or healthy ageing are not established by the ileus programme or by an acute GH pulse. Those propositions require their own route-specific pharmacokinetics, functional outcomes and longitudinal metabolic assessment. | [1][2] |
| IVIntegrated in-vivo model | Translation beyond the studied indication · claim 2 | Repeated stimulation of the GH/IGF-1 axis raises monitoring questions around glucose regulation, oedema, paraesthesia and proliferative context. These are mechanistically foreseeable domains, while their magnitude under a particular regimen remains an empirical question. | [1] |
Methods and coverage
A reproducible boundary, not an implied exhaustive review.
This is a curated mechanistic monograph built from primary records. It does not claim systematic-review completeness. Absence of a retrieved result is not evidence that an effect is absent.
- SEARCH SURFACE
- PubMed/MEDLINE primary records, Russian-language indexed abstracts, and reference-chaining for entity-defining, historical and translational studies. Language, geography, regulatory status and journal fashion are not evidence grades.
- QUERY FRAME
- ipamorelin · GHSR1a · ghrelin receptor · growth hormone secretagogue · pharmacokinetics · postoperative ileus
- EVIDENCE CUTOFF
- 23 August 2026
- ENTITY EXCLUSION
- Ipamorelin evidence cannot be transferred from ghrelin, other GHRPs, oral ghrelin agonists or CJC combinations. Route and pulse kinetics are part of identity-in-use.
- TRACEABILITY
- 10 extended claim units plus 2 historical records and 3 mechanistic-calculus records; 4 cited records in the complete corpus.
- INTERPRETIVE RULE
- Identity → physical constraint → measured reaction or binding → reachable exposure → system response → outcome. Statistical significance does not manufacture mechanism; mechanistic plausibility does not manufacture a patient outcome.
Falsification map
What could make the proposition wrong?
A scientific monograph must state not only why a mechanism may hold, but what observation would weaken or overturn the inference.
- 01Absent GH movement after verified exposure would challenge target engagement.
- 02Repeated pulses without outcome improvement would refute GH-response-as-clinical-response reasoning.
- 03The controlled ileus result already falsifies a reliable benefit claim for the studied regimen and endpoint.
Research agenda
What would materially change the conclusion?
A useful research agenda resolves the weakest link in the identity-to-outcome chain. It does not merely add more observations of the same type.
- 01Subcutaneous and intranasal route-specific PK
- 02Repeated-dose GH and IGF-1 dynamics
- 03Controlled recovery and body-composition outcomes
- 04Glucose and sleep-related effects
- 05Predictors of response despite the negative ileus trial
Cited primary evidence corpus
4 source records used in this publication.
Reference numbers resolve directly to indexed records. This corpus documents the claims made here; it is not presented as an exhaustive systematic-review search. Index access does not upgrade the evidentiary class of a study.
- [1]Gobburu et al. Pharm Res. 1999;16:1412–1416.PMID 10496658 ↗
- [2]Beck et al. Int J Colorectal Dis. 2014;29:1527–1534.PMID 25331030 ↗
- [3]Venkova et al. Ipamorelin accelerates gastric emptying in a rodent model of postoperative ileus. Exp Biol Med. 2016.PMID 27186127 ↗
- [4]Raun et al. Eur J Endocrinol. 1998;139:552–561.PMID 9849822 ↗
Permanent citation
Cite this publication
Wibowo V. Ipamorelin: Biochemical, Mechanistic and Physiological Monograph. Clinic Terrain Clinical Intelligence Unit. Version 5.0. Updated 23 August 2026.
https://www.clinicterrain.com/research/peptides/ipamorelinPublication and reference-verification method →Authorship and accountability
Valentine Wibowo, Clinical Researcher, Clinic Terrain Clinical Intelligence Unit, performed the conceptualisation, evidence synthesis, scientific interpretation and drafting. dr. I Wayan Cahyadi Surya Distira Putra, MPH completed medical review and approved the publication. Internal medical review is not represented as independent peer review.
No new patient data or human research were undertaken. The author and reviewer declare no personal financial competing interests. Clinic Terrain and Klinik Pratama Cepat Sehat provide clinical services; that institutional relationship is disclosed.